Dodson Rebecca M, He Jin, Pawlik Timothy M
Johns Hopkins University School of Medicine, Department of Surgery, 600 North Wolfe Street, Blalock 688, Baltimore, MD 21287, USA.
Future Oncol. 2014 Mar;10(4):587-607. doi: 10.2217/fon.13.225.
The management of hepatocellular carcinoma within the Milan criteria and with well-compensated cirrhosis is a topic of debate. Recent surveillance programs in patients with hepatitis C and cirrhosis have allowed some patients to be diagnosed with early, potentially curable, disease via liver resection (LR), liver transplantation (LT) or liver ablation. LT has excellent outcomes with 5-year survival rates >70% for patients within the Milan criteria. However, its utilization is limited by increasing organ shortages. LR is also effective with 5-year survival outcomes between 50-70% and safe in light of advances in surgical technique, preresection optimization and patient selection. Patients with solitary tumors and well-preserved liver function are good candidates for LR, whereas LT is best reserved for patients with compromised liver function and multifocal disease. LT and LR should not be viewed as competing tools but as complementary tools in the current armamentarium to treat early hepatocellular carcinoma.
米兰标准内且肝硬化代偿良好的肝细胞癌管理是一个存在争议的话题。近期针对丙型肝炎和肝硬化患者的监测项目使一些患者能够通过肝切除(LR)、肝移植(LT)或肝消融术被诊断出早期、可能治愈的疾病。对于符合米兰标准的患者,LT具有出色的治疗效果,5年生存率>70%。然而,可用器官的日益短缺限制了其应用。LR也很有效,5年生存率在50 - 70%之间,并且鉴于手术技术、术前优化和患者选择方面的进展,LR是安全的。孤立肿瘤且肝功能良好的患者是LR的良好候选者,而LT最适合肝功能受损和多灶性疾病的患者。在当前治疗早期肝细胞癌的手段中,LT和LR不应被视为相互竞争的工具,而应被视为互补的工具。